08:35 AM EDT, 03/10/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday that its potential ulcerative colitis treatment icotrokinra met the primary endpoint of clinical response in all dosages in a 252-patient phase 2b study.

The investigational drug also showed "clinically meaningful" differences versus placebo in secondary endpoints of clinical remission, symptomatic remission, and endoscopic improvement at week 12, the company said.

Icotrokinra at the highest doses showed a response rate of 63.5% for patients with chronic large intestine disease after 12 weeks, versus 27% for placebo, and a remission rate of 30.2%, versus 11.1% for the placebo, the company said.

It added that remission and response rates continued to improve through week 28.